Inspire HGNS denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for inspire hgns are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denies Inspire HGNS as Experimental — and How to Respond

A UnitedHealthcare "experimental or investigational" denial for hypoglossal nerve stimulation is among the most directly rebutted denials you are likely to encounter, because it conflicts with factual public record. The Inspire Upper Airway Stimulation system holds FDA Premarket Approval (PMA) — the highest tier of FDA device authorization, requiring demonstrated safety and effectiveness. PMA-approved devices are, by regulatory definition, not unapproved or purely investigational.

UHC applies its own internal evidentiary standard (typically requiring randomized controlled trial evidence and/or professional society adoption) when making experimental determinations. For Inspire HGNS, that standard has been met: major professional organizations in sleep medicine and otolaryngology have recognized HGNS in their guidance documents, and UHC's own published Coverage Determination Guidelines for HGNS — which list specific coverage criteria — implicitly acknowledge that the technology is not experimental when criteria are met. A blanket "experimental" denial that ignores UHC's own criteria-based coverage guideline is internally inconsistent and ripe for reversal.

## Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): Submit a full written appeal with FDA approval documentation and professional society references. For experimental denials, the appeal record is especially important because external reviewers will scrutinize UHC's evidentiary basis.
• External review: After a final internal denial, you are entitled to independent external review, generally within approximately four months. External reviewers apply objective clinical standards, not UHC's internal policy thresholds.
• Timeline: Do not miss the external review deadline on your denial notice.
• Expedited review: Available for urgent situations — typically decided within 72 hours.

## What to Gather

1. FDA PMA documentation — the public FDA summary for the Inspire HGNS PMA, available at fda.gov/medical-devices. Print or save the approval record showing PMA status and approved indication for OSA. 2. Professional society guidance — copies of position statements or clinical practice guidance from the American Academy of Sleep Medicine (AASM) and/or the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) recognizing HGNS as an evidence-based treatment. 3. UHC's own coverage determination guideline — download the current UHC Coverage Determination Guideline for hypoglossal nerve stimulation from uhcprovider.com. If it lists coverage criteria, cite it as evidence that UHC itself does not categorically classify HGNS as experimental. 4. Prescriber letter — your surgeon or sleep physician should directly rebut the experimental characterization by citing FDA approval, society guidance, and the fact that the device is being used for its FDA-approved indication in a patient who meets the published criteria. 5. Diagnosis and clinical qualification — polysomnography confirming OSA diagnosis and severity; PAP failure documentation with dates and objective data.

## Criteria-Mapping Structure

| UHC Experimental Determination Basis | Rebuttal Evidence | |---|---| | [Any specific evidentiary standard cited in the denial] | [FDA PMA record; society guideline citation] | | [Absence of coverage criteria claim, if made] | [UHC's own coverage guideline listing criteria] | | [Clinical appropriateness for this patient] | [Sleep study, PAP failure data, prescriber letter] |

Your appeal letter should state plainly: the device holds FDA PMA approval; applicable professional medical societies recognize it as evidence-based; and UHC's own published coverage guideline acknowledges coverage when clinical criteria are met. Request that UHC identify the specific evidentiary basis for classifying an FDA PMA-approved device as experimental, as required under ERISA §503.